Viromed Medical AG Announces Plans to Acquire ActivCell Group AG

Viromed Medical AG intends to acquire all shares of ActivCell Group AG through a capital increase against contributions in kind, excluding subscription rights, according to Article 17 MAR of the EU Regulation No 596/2014. The Pinneberg-based medical company aims to augment its product range and expects to quicken the launch of its own cold plasma products in the European Union.

ActivCell Group AG specializes in the development of cold plasma therapy pens, gaining approval under the Medical Device Regulation (MDR) 2017/745 for treating skin and wounds. This strategic acquisition will bolster Viromed's offerings in the healthcare market.

Viromed anticipates completing the transaction within the current financial year, with a purchase price in the mid-single-digit million-euro range. The acquisition will be financed solely by issuing new shares, utilizing Viromed's Authorized Capital 2022, excluding shareholders' subscription rights.

Finalization of the deal hinges on reaching an agreement with ActivCell Group AG's shareholders. Additional discussions and negotiations will proceed immediately to cement the arrangement.